Form 4: Roivant Sciences Director Melissa Epperly Receives Stock Options and Restricted Stock Units

Director Melissa Epperly received stock options and restricted stock units from Roivant Sciences as part of the company's 2021 Equity Incentive Plan and Non-Employee Director Compensation Policy.

Summary

• Melissa Epperly, a director at Roivant Sciences Ltd., received an annual award of 16,406 restricted stock units (RSUs) and 27,894 stock options on September 10, 2024.
• The RSUs and stock options were granted under the company's 2021 Equity Incentive Plan and Non-Employee Director Compensation Policy.
• The RSUs will vest 100% on September 10, 2025, contingent upon Epperly's continuous service through that date.
• The stock options, with an exercise price of $12.19, will also vest and become exercisable 100% on September 10, 2025, subject to continued service, and expire on September 9, 2034.
• Following these transactions, Epperly directly owns 40,669 common shares and 27,894 stock options.

Sentiment

Score: 7

Explanation: The document reflects a standard compensation practice, indicating a stable and well-governed company. The sentiment is neutral to positive as it aligns director interests with shareholders.

Positives

• The grant of RSUs and stock options aligns the director's interests with those of the shareholders, incentivizing her to contribute to the company's long-term success.
• The vesting schedule encourages continued service and commitment from the director.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

Granting stock options and RSUs to directors is a common practice in the pharmaceutical and biotechnology industries to align their interests with those of shareholders and incentivize long-term value creation.

Comparison to Industry Standards

• Stock option and RSU grants are standard compensation practices for directors in publicly traded companies, particularly in the biotech and pharmaceutical sectors.
• Companies like Pfizer, Johnson & Johnson, and AbbVie also utilize similar equity-based compensation plans for their directors.
• The vesting schedules and exercise prices are generally aligned with industry norms to incentivize long-term performance and retention.

Stakeholder Impact

• Shareholders may view the equity grants positively as they align the director's interests with the company's long-term success.
• Employees may see this as a sign of a healthy and stable company.

Key Dates